ArticleNature communications2017
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05119010 (A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma), which is not on this map. Cited by 169 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Who cites it
169 citing papers in PubMed, 1 synthesis or guideline pooled it, 243 citations in OpenAlex.
- Disrupting Mechanisms that Regulate Genomic Repeat Elements to Combat Cancer and Drug Resistance.Frontiers in cell and developmental biology · 2022Pooled it
- Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapy.Research square · 2026Article
- Therapy-induced senescence rewires the melanoma secretome to promote antitumor immune response and augment cell therapies.Journal for immunotherapy of cancer · 2026Article
- PD-1/PD-L1 inhibitor induces systemic inflammation and alters cardiac lipid metabolism in C57BL/6 J mice.Human cell · 2026Article
- Single-Cell Analysis Identifies LYPD6B as a Tumor-Intrinsic Candidate Associated With Immunotherapy Nonresponse in Breast Cancer.Thoracic cancer · 2026Article
- JAK-STAT signaling pathway in cancer: from molecular mechanisms to clinical intervention.Molecular cancer · 2026Review
- Dynamic ecosystems of tumor drug resistance mechanisms: from molecular heterogeneity to systemic interventions.Apoptosis : an international journal on programmed cell death · 2026Review
- Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance.Genes & development · 2026Article
- Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas.Journal for immunotherapy of cancer · 2026Article
- Bridging cancer cell-intrinsic driver genes and -extrinsic cell-cell communication with Driver2Comm.PLoS computational biology · 2026Article
- Beyond local control: radiotherapy-immunotherapy combinations fromFrontiers in genetics · 2026Review
- Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges.Frontiers in oncology · 2026Review
- Recombinant human adenovirus type 5 synergizes with anti-PD-L1 antibody to promote anti-hepatocellular carcinoma effects through multilevel remodeling of the immune microenvironment.Frontiers in immunology · 2026Article
- Advances in Targeted and Immunotherapy for High-Risk Cutaneous Malignancies.Oncology research · 2026Review
- Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives.Frontiers in oncology · 2026Review
- The IFN-γ response cycle: decoupling tumor killing from evolutionary selection in cancer immunotherapy.Frontiers in immunology · 2026Review
- Mechanisms of Immune Checkpoint Inhibitor Resistance in Hepatocellular Carcinoma and Strategies for Reversal.Cancers · 2025Review
- A Comparative Analysis Dissecting the Immune Landscape of Vitiligo and Melanoma from a single-cell Perspective: Two Sides of the Same Coin?Inflammation · 2025Article
- Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2025Article
- Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance.bioRxiv : the preprint server for biology · 2025Article
109 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 2 countries.
Antje SuckerDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Fang ZhaoDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Natalia PieperDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Christina HeekeDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Raffaela MaltanerDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Nadine StadtlerDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Birgit RealDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Nicola BielefeldDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Sebastian HoweInstitute of Virology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Benjamin WeideDivision of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, 72076 Tübingen, Germany.
Ralf GutzmerDepartment of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, 30625 Hannover, Germany.
Jochen UtikalGerman Cancer Research Center (DKFZ), Skin Cancer Unit, Heidelberg and University Medical Center Mannheim, Department of Dermatology, Venereology and Allergology, Ruprecht-Karl University of Heidelberg, 68167 Mannheim, Germany.
Carmen LoquaiSkin Cancer Center, Department of Dermatology, University of Mainz Medical Center, 55131 Mainz, Germany.
Helen GogasFirst Department of Medicine,National and Kapodistrian University of Athens, 11527 Athens, Greece.
Ludger Klein-HitpassInstitute of Cell Biology, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany.
Michael ZeschnigkInstitute of Human Genetics, University Hospital Essen, University Duisburg-Essen, West German Cancer Center and the German Cancer Consortium (DKTK), 45122 Essen, Germany.
Astrid M WestendorfInstitute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany.
Mirko TrillingInstitute of Virology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Susanne HornDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Bastian SchillingDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Dirk SchadendorfDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Klaus G GriewankDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Annette PaschenDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
University of Duisburg-Essen · DEDeutschen Konsortium für Translationale Krebsforschung · DEHeidelberg University · DEMedizinische Hochschule Hannover · DENational and Kapodistrian University of Athens · GRUniversitätsklinikum Würzburg · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma treatment has been revolutionized by antibody-based immunotherapies. IFNγ secretion by CD8
Indexed as
Antigen PresentationAntigens, NeoplasmAntineoplastic Agents, ImmunologicalBiopsyCell Line, TumorDatasets as TopicDNA Mutational AnalysisDrug Resistance, NeoplasmHistocompatibility Antigens Class IHumansImmunotherapyInterferon-gammaJanus Kinase 1Janus Kinase 2MelanomaMutationAntigens, NeoplasmAntineoplastic Agents, ImmunologicalHistocompatibility Antigens Class IInterferon-gammaJAK1 protein, humanJAK2 protein, humanJanus Kinase 1Janus Kinase 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05119010ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.